The transition from on-premise PACS to cloud-based enterprise imaging platforms is the most consequential commercial shift in radiology informatics in a generation. GE HealthCare's planned $2.3 billion acquisition of Intelerad — a leading cloud-based enterprise imaging company — signals the strategic importance of cloud imaging infrastructure to the large OEMs. Vendor neutral archives, cloud PACS, and AI-integrated enterprise imaging platforms are replacing traditional modality-specific storage and review systems across health systems globally.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• Cloud PACS Market Dynamics
• Vendor Neutral Archives
• Enterprise Imaging Platforms
• OEM Cloud Strategy — GE Intelerad, Siemens syngo.via, Philips IntelliSpace
• AI Integration in Enterprise Imaging
• SaaS Pricing Models
• Cybersecurity Requirements...

Value-based care models — particularly Medicare's Comprehensive Care for Joint Replacement bundled payment program and its successor models — are fundamentally changing how orthopedic implants and services are purchased and reimbursed. Under bundled payments, hospitals and surgeons share financial risk for the total cost of a joint replacement episode, creating powerful incentives to select implants and technologies that reduce complications, readmissions, and extended care utilization.

Topics Covered
• CJR and Bundled Payment Models
• Outcomes Measurement Frameworks
• Implant Cost in Bundled Episodes
• OEM Value-Based Contracting
• Real-World Evidence and Outcomes Data
• Post-Acute Care Optimization...

Implant materials science is a persistent source of competitive differentiation in orthopedics. Titanium alloy, cobalt-chromium, ultra-high molecular weight polyethylene, PEEK, and ceramic materials each offer distinct combinations of mechanical performance, biocompatibility, imaging compatibility, and manufacturing economics. Surface treatment technologies — hydroxyapatite coating, titanium plasma spray, trabecular metal — directly influence osseointegration and cementless fixation performance.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• Titanium and Cobalt-Chrome Alloys
• PEEK in Spine and Extremities
• Ceramic Bearings in Hip Arthroplasty
• UHMWPE and Crosslinked Polyethylene
• Surface Coating Technologies
• Additive Manufacturing for Implants
• Antibacterial and Bioactive Surfaces...

Aesculap is B. Braun subsidiary and one of the world's leading orthopedic suppliers.

Aesculap — the surgical instruments and orthopedic implants division of B. Braun — is one of Europe's leading orthopedic suppliers with particular strength in spine, trauma, cranio-maxillofacial, and surgical instruments. Headquartered in Tuttlingen, Germany — the global capital of surgical instrument manufacturing — Aesculap benefits from B. Braun's $10.8 billion global healthcare platform while maintaining a focused orthopedic and surgical specialization. The company's spine portfolio, trauma fixation systems, and hip and knee reconstruction implants serve a predominantly European and emerging market customer base through a combination of direct sales and distributor networks.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• Acquisitions and divestitures
• Marketing tactics
• Financial results
• Strengths...

Arthrex is privately held and one of the world's leading orthopedic suppliers.

Arthrex is a privately held global medical device company specializing in orthopedic surgery, sports medicine, and minimally invasive surgical technologies. Founded in 1981 and headquartered in Naples, Florida, the company has grown into one of the leading innovators in the global orthopedics industry with a presence in more than 100 countries. Its business is centered on developing and commercializing products that support the surgical treatment of musculoskeletal conditions — with particular strength in arthroscopic surgery, sports medicine implants, orthobiologics, and surgical enabling technology. A defining feature of Arthrex's business model is its emphasis on surgeon education and training, with a global network of cadaveric and simulation-based training centers that generates surgeon loyalty through knowledge transfer.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D program...

DePuy Synthes/J&J is J&J MedTech division and one of the world's leading orthopedic suppliers.

DePuy Synthes — operating within Johnson & Johnson MedTech — is the world's largest orthopedic company by revenue with a comprehensive portfolio spanning joint reconstruction, trauma and extremities, spine, craniomaxillofacial, and surgical enabling technology. As part of J&J MedTech reporting approximately $34 billion in total MedTech revenues in 2025, DePuy Synthes benefits from J&J's global commercial infrastructure, regulatory capability, and financial resources. The Velys Robotic-Assisted Solution for total knee arthroplasty represents DePuy Synthes's primary competitive response to Stryker's Mako platform and has reached over 500 installed systems globally.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• Acquisitions and divestitures
• Marketing tactics
• Financial results
• Strengths and weakn...

Enovis is formerly Colfax Corporation and one of the world's leading orthopedic suppliers.

Enovis is a medical technology company focused on musculoskeletal health — formed through the 2022 transformation of Colfax Corporation and the 2023 acquisition of LimaCorporate. The company's Reconstructive segment, which includes the DJO and Lima brands, provides hip and knee reconstruction implants alongside a significant orthopedic bracing and recovery portfolio. Enovis is executing a focused strategy of building orthopedic reconstruction scale through organic growth and bolt-on acquisitions while leveraging its established position in functional bracing and rehabilitation devices.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• Acquisitions and divestitures
• Marketing tactics
• Financial results
• Strengths and weaknesses
• Strategic directions...

The migration of total joint arthroplasty — historically performed exclusively in hospital inpatient settings — to ambulatory surgery centers is the most consequential channel shift in orthopedics. CMS removal of total knee and hip arthroplasty from the Inpatient Only list, combined with advances in anesthesia, pain management, and enhanced recovery protocols, has enabled same-day discharge for a growing proportion of primary joint replacement patients.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• ASC Market Size and Growth
• Procedure Migration Economics
• CMS Reimbursement Policy
• OEM ASC Commercial Strategy
• Implant and Instrument Design for ASC
• Hospital vs. ASC Competitive Dynamics...

The global orthopedics market is valued at approximately $55 billion in 2026 and is growing at approximately 4-5% annually, driven by aging populations in developed markets, rising surgical volumes in emerging markets, and the commercial momentum of robotic-assisted surgery. The market is concentrated among a small number of large-scale suppliers — Stryker, DePuy Synthes/J&J, Zimmer Biomet, Smith & Nephew, and Medtronic collectively accounting for the majority of global revenues — alongside a tier of focused innovators including Arthrex, Globus Medical, and Enovis.

Robotic-assisted surgery is the most commercially consequential technology transition in orthopedics since the introduction of cementless fixation. Stryker's Mako platform with over 1,800 installed systems globally has established a virtuous commercial cycle that competitors are racing to replicate. Zimmer Biomet's ROSA, Globus Medical's ExcelsiusGPS, DePuy Synthes's Velys, and Smith & Nephew's CORI represent the competitive response — but Mako's installed base lead and pull-through model create a du...

This report delivers comprehensive strategic intelligence on the world's leading orthopedics companies. The global orthopedics market is valued at approximately $58 billion in 2026. Stryker leads with orthopedic revenues of approximately $14 billion. Zimmer Biomet generates approximately $7 billion. DePuy Synthes, part of Johnson & Johnson MedTech, generates approximately $9 billion. The industry is being transformed by surgical robotics, AI-powered implant planning, biologics integration, and value-based care contracting.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Companies Analyzed in This Report:
Aesculap
Arthrex
DePuy Synthes
Enovis
Globus Medical
NuVasive
Smith & Nephew
Stryker
Wright Medical
Zimmer Biomet

The Analysis of Each Company Includes:
• Strategic Directions and Corporate Priorities
• Financial Performance and Revenue Breakdown
• SWOT Analysis
• Technological Kn...

Robotic-assisted surgery is the most commercially significant technology transition in orthopedics in a generation. Stryker's Mako platform — with over 1,800 installed systems globally — has established the commercial template: capital equipment placement drives implant pull-through, increases procedure volume, and creates switching costs that defend market share against price competition. Every major orthopedic OEM is now competing to establish a comparable robotics installed base.

Zimmer Biomet's ROSA has reached over 1,200 installations. Globus Medical's ExcelsiusGPS leads in spine robotics with over 800 systems and is expanding into hip arthroplasty. DePuy Synthes's Velys has reached over 500 installations. Smith & Nephew's CORI is growing. The competitive dynamics of the robotics installed base race will determine market share in joint reconstruction and spine for the next decade.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


...